Drug Delivery

Nasal Drug Spray Device Testing

Aerosol, spray, dose, breathing-simulation, and stability testing for nasal drug spray devices and formulations.

We use NGI with nasal fixtures, laser diffraction, APS, dose collection, breathing profiles, and HPLC or ELISA quantitation matched to the active.

ISO 17025USP <601>FDA MDI / DPI / nasalReviewed 2026-10-20
Scope a nasal spray studySubmit a sample

Testing nasal drug spray devices

Nasal drug spray testing gives sponsors in vitro performance data to select pumps, compare formulations, document change control, and support submission packages. Study planning draws on USP <601>, FDA nasal spray guidance, and ICH Q1A for droplet size, spray geometry, dose output, breathing-interface behavior, and stability trending. Common uses include:

  1. PSD by laser diffraction, APS, or NGI compares nasal spray droplet and aerodynamic profiles under USP <601> and FDA nasal guidance.
  2. Spray pattern and plume geometry document actuator, nozzle, pump, or formulation changes for FDA comparability and change-control packages.
  3. Delivered dose and emitted dose series quantify actuation variability, priming, and container-life effects under USP <601>.
  4. Breathing simulation estimates inhaled or beyond-nose fraction using nasal fixtures, interface geometry, and FDA use-condition framing.
  5. Stability pulls track PSD, plume, dose, assay, and device behavior after ICH Q1A temperature and RH conditioning.

Use nasal spray testing when device output, formulation state, actuation settings, or storage history could affect delivered performance. Before samples arrive, the protocol links fixture geometry, actuation sequence, particle measurement, analytical recovery, and acceptance logic. USP <1601> applies to pulmonary products for nebulization; it is not a general nasal spray method reference.

Core testing menu for nasal drug spray devices

Nasal spray programs draw on five measurement disciplines. Select one endpoint or combine several based on formulation stage, comparator strategy, use condition, and regulatory context.

Test method options

MethodStrengthsTradeoffAligned with
Submission-grade PSD and APSD package
  • Laser diffraction plus NGI collection quantifies droplet size, MMAD, GSD, and small-particle fraction under USP <601>.
  • Recovery controls and nasal fixtures connect stage mass to FDA nasal spray comparability and submission support.
Higher setup and assay burden than screening; best after pump, nozzle, formulation, and collection conditions are selected.
USP <601>FDA MDI / DPI / nasal
Spray pattern and plume geometry study
  • Laser sheet imaging resolves spray footprint, plume angle, width, and distribution for FDA change-control studies.
  • Controlled distance, timing, and actuation settings isolate pump, actuator, nozzle, or formulation effects.
Geometric imaging does not replace APSD or dose data when regulators require active-mass endpoints.
FDA MDI / DPI / nasalISO 27427
Dose uniformity and emitted dose series
  • Multi-actuation sequences measure delivered dose, emitted dose, priming, repriming, and container-life effects under USP <601>.
  • HPLC, ELISA, qPCR, or ddPCR recovery links collection mass to active-specific dose statistics.
Collection adapters and actuation settings must match device geometry before meaningful lot comparisons can start.
USP <601>FDA MDI / DPI / nasal
Breathing-interface and use-condition simulation
  • Programmable profiles pair actuation timing, nasal fixtures, and recovery locations to estimate inhaled fraction under USP <601>.
  • Profile sweeps support FDA use-condition comparisons without changing the active assay or device state.
Results depend on fixture assumptions, leakage, and profile selection; those assumptions must be declared up front.
USP <601>ISO 27427FDA MDI / DPI / nasal
Stability-linked performance trending
  • Conditioned pulls track PSD, plume, emitted dose, assay, and pump function across ICH Q1A storage timepoints.
  • Distribution or handling conditioning can add ASTM D4169 stress before post-aging nasal spray performance checks.
Study duration follows storage and pull timing; analytical scheduling should be planned before conditioning begins.
ICH Q1AASTM D4169

Setup configurations

We plan each nasal spray study around device geometry, formulation state, the collection endpoint, and the intended regulatory use. One product may need different fixtures for droplet sizing, APSD, plume imaging, dose recovery, breathing simulation, or stability pulls. Before testing begins, we define actuation settings, environmental controls, assay recovery, and replicate structure.

Interfaces & fixtures

Nasal adapters, throat models, bottle holders, and recovery fixtures matched to the pump, actuator, nozzle, and container geometry.

Actuation profiles

Manual, semi-automated, or automated actuation with force, stroke, speed, priming, repriming, shot interval, and orientation recorded per run.

Flows & breathing profiles

Collection flow, breathing waveform, sampling location, and fixture leakage controls set to the endpoint and use-condition question.

Sample numbers

Device count, lot count, spray count, life stage, and replicate count sized to screening, comparability, stability, or submission support.

Conditioning & controls

Temperature, RH, storage orientation, blanks, reference devices, recovery locations, assay controls, and acceptance criteria defined before interpretation.

Quality frame for nasal spray testing

ARE Labs runs nasal spray studies within a documented quality system, drawing on the compendial and regulatory references most often used for intranasal drug products and development decisions.

  • ISO 17025AccreditedLaboratory competence, calibration traceability, method control, and uncertainty contributors.
  • USP <601>AccreditedAerosols, nasal sprays, APSD, delivered dose, and spray-performance tests.
  • FDA MDI / DPI / nasalAlignedCMC expectations for nasal spray product quality attributes and changes.

Key data outputs & reporting

Reports connect the nasal spray device setup to measured performance through endpoint-specific datasets: PSD tables, APSD recovery, emitted-dose statistics, plume images, breathing-profile recovery, assay controls, and QA/QC records. We format reports for development review, method justification, comparability packages, or interpretation of stability trends. When a program includes predicate comparisons or storage pulls, extended deliverables include the appendices needed to document that work.

Primary outputs

  • Droplet size distribution, APSD stage mass, MMAD, GSD, small-particle fraction, and impactor recovery by device or condition.
  • Spray pattern area, circularity, plume angle, plume width, distance setting, actuation timing, and image files.
  • Delivered dose, emitted dose, priming, repriming, beginning/middle/end-of-life statistics, mean, SD, and %RSD.
  • Breathing-profile recovery by fixture location with profile assumptions, flow settings, leakage notes, and interpretation limits.

Deliverables

#FormatContents
01PDF reportProtocol summary, setup, controls, deviations, results, and interpretation limits.
02CSV / XLSX datasetsParticle sizing, stage mass, dose statistics, recovery, and assay tables.
03Images / videoSpray pattern files, plume frames, overlays, and high-speed exports when used.
Extended deliverables · multi-arm comparability · stability · predicate studies
  • Comparability appendix — Side-by-side PSD, APSD, plume, and dose summaries for reference, predicate, or design-change review.
  • Stability trend pack — Timepoint tables and figures showing dose, size, plume, assay, and device-function drift.
  • Method-development notes — Fixture rationale, control runs, recovery constraints, and uncertainty contributors for inspection readiness.

QA / QC & data integrity

Each nasal spray study has a QA/QC plan matched to its endpoints, assay, and regulatory context. We run controls alongside sample collection so particle, plume, dose, and breathing-simulation data remain traceable from sample receipt through the final report. The report also documents method deviations, invalid runs, and contributors to uncertainty.

Blanks, background checks, comparator devices, or reference runs defined by endpoint and collection train.

Flow meters, balances, impactor stages, imaging scales, timers, and actuation fixtures checked or calibrated before use.

Assay controls for HPLC, ELISA, qPCR, or ddPCR, including calibration standards and recovery checks when required.

Chain of custody for devices, collected stages, filters, extracts, raw files, image files, and analyst observations.

Predefined acceptance criteria, replicate rules, deviation handling, and outlier logic included in the protocol.

RESEARCH / THIS WORK IN PRACTICE

Real studies. Measured evidence.

Explore published studies connected to nasal spray. Each explains the study question, approach and findings.

View related studies (1)
Inhalation & Drug Delivery

Dry-Powder Nasal Spray Testing: Phase 1 Characterization

The study established an early performance baseline for comparing the two variants and provided data for a regulatory-facing Phase 1 characterization package. It did not assess clinical efficacy or support claims of approval.

Selected finding
Recovered material was predominantly classified in the nasal or upper-airway region for both variants.
Related context

The published study characterizes two dry-powder nasal spray dose variants.

Nasal deliveryParticle sizingDevice evaluation

Study-specific findings do not guarantee performance for another product.

Why ARE Labs

ARE Labs connects technical topics to practical study design, method selection, controlled aerosol work, and reportable evidence without turning technical pages into sales pages.

Reviewed byJamie Balarashti (25 yrs - cascade & inhalation methods) - Weston Schaper (7 yrs - real-time sizing & nanoparticle work)
QualityDocumented study records
900+Studies Performed
17+Years in operation
300+Clients supported

Common questions

These answers cover questions nasal drug spray development and regulatory teams commonly ask when planning a study: which endpoints to combine, how devices and actuations are counted, what breathing simulation changes, and what documentation they receive. Most nasal spray programs need at least one decision about a custom fixture, actuation, or assay. Study planning is the best time to resolve it.

Q.Which nasal spray test should I start with?
A.Start with the decision you need to make. PSD describes size distribution, plume imaging shows spray formation, and dose testing measures output consistency. Breathing simulation evaluates recovery under use conditions, while stability testing tracks storage effects.
Q.Do I need both plume geometry and PSD?
A.Often, yes. Spray pattern and plume geometry describe how the spray forms, while PSD and APSD describe particle or droplet size behavior. Submission and comparability packages commonly need both endpoint families.
Q.How many devices or actuations are needed?
A.We define device count, lot count, shot count, life stage, and replicate count during protocol development. Those choices depend on variability, assay sensitivity, and whether the work is for screening or submission support.
Q.Can ARE Labs test solution and suspension sprays?
A.Yes. The protocol can address solution or suspension behavior, including shaking, settling, recovery, active assay, droplet size, emitted dose, and stability-linked performance checks.
Q.Does this certify or approve a nasal spray product?
A.No. ARE Labs provides focused aerosol, emitted dose, breathing simulation, assay, and stability testing. Sponsors may still need clinical, bioequivalence, labeling, submission, and quality-system work.

Standards & guidance

ARE Labs aligns nasal spray test programs with the compendial, consensus, and regulatory references used for intranasal product characterization. Accredited scopes are reported as accredited; other references are followed as aligned or conformant where applicable. The rows below list the standards and guidance clusters most often cited for nasal spray sizing, plume, dose, breathing-interface, and stability support.

Inhalation & Drug Delivery - Accredited

USP <601>

Aerosols, nasal sprays, APSD, delivered dose, and performance quality testsView standard ->QA & Regulatory - Aligned

FDA MDI / DPI / nasal

Quality considerations for nasal spray products, comparability, device changes, and CMC supportView standard ->Inhalation & Drug Delivery - Aligned

ISO 27427

Nebulizing system performance concepts used where breathing-interface evaluation appliesView standard ->QA & Regulatory - Aligned

ICH Q1A

Stability storage conditions, pull timing, and trend interpretation for drug productsView standard ->Packaging & Stability - Aligned

ASTM D4169

Distribution-cycle conditioning before post-stress nasal spray performance evaluationView standard ->

Related testing services

Test

Particle Size Distribution (PSD) Testing

Pairs with nasal spray dose testing to quantify droplet size, APSD, MMAD, GSD, and small-particle fraction.Read more ->Test

Spray Pattern & Plume Geometry

Documents pump, actuator, nozzle, and formulation effects on plume shape, spray footprint, and spray distribution.Read more ->Test

Dose Uniformity & Emitted Dose

Core nasal spray output test for actuation consistency, priming, repriming, and container-life dose behavior.Read more ->Test

Breathing Simulation Testing

Adds use-condition profiles, nasal fixtures, interface geometry, and recovery locations for inhaled or beyond-nose fraction questions.Read more ->Test

Stability & Accelerated Aging

Pairs storage pulls and conditioning with nasal spray PSD, plume, dose, assay, and pump-function trending.Read more ->